Drug Discovery

#AI #Drug discovery #United States

From the Editor: A year in turmoil

For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position… Read More

#Exclusive Content #Opinion

#Drug discovery #Multiomics

Webinar – MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases.  End-to-end solutions range from sourcing and managing samples to standardised preparation, cutting-edge mass spectrometry, and advanced in-house data analysis. What’s more, tailored MS-based assays enable high resolution or high throughput… Read More

#Webinars

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Mapping disease trajectories with proteomics

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma… Read More

#Exclusive Content

#Cell Science #Drug discovery

Webinar – Advancing protein analysis with high-throughput multiplexed fluorescence westerns

In this webinar, hosted by DDW, Bio-Techne will unveil the next evolution of the Leo™ System, expanding the capabilities of Simple Western™ Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples… Read More

#Webinars

Proteomics
#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Watch now: How can targeted proteomics accelerate drug discovery?

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More

Webinar date:
Supported by Evotec
#News

Lab automation and robotics
#Automation / robotics #Drug discovery #eBook #Lab automation

DDW eBook: Lab automation – how technology can accelerate drug discovery

The lab automation market in the drug discovery sector is estimated to grow from $5.90 billion in 2026 to reach $7.27 billion by 2031. This is according to Mordor Intelliogence. It adds that the growth reflects the “steady integration of artificial intelligence into laboratory workflows, the mainstream adoption… Read More

#News

Conference microphone
#Artificial intelligence (AI) #Events #Lab technology #SLAS2026

‘Creating Cures’ at SLAS2026: Full speaker line-up announced

For the third year running DDW is organising a series of seminars at SLAS International Conference and Exhibition. Based on the SLAS2026 theme of Catalyze Discovery, these will be available to visitors of SLAS2026 (7-11 February 2026, Boston, USA). The programme – Creating Cures: The role… Read More

#Editor's Choice #News

2026 ideas
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #Gene editing

CGT in 2026: In vivo, greater specificity and next-gen platforms

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. Read More

#Exclusive Content #Trends & Analysis

Lab equipment
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: Discover a powerful solution for mechanism-of-action studies

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

#AI / data analytics / healthtech / informatics #Alzheimer's #Drug discovery #Oncology #Regulatory #Spatial biology

DDW Winter issue out now

The DDW Winter 2025/2026 issue is out now and includes features covering the advances and challenges in blood cancer drug development, how the Baltics is implementing a new action plan for its life sciences sectors, and how spatial epigenetics is unlocking new frontiers for drug discovery.  It also… Read More

#News

#AI #Clinical trial #Drug discovery #Parse Biosciences

Life science partnership to improve AI-driven drug discovery  

Life sciences company Parse Biosciences has partnered with research institute Graph Therapeutics to create what it says is one of the largest and most comprehensive immune cell perturbation atlases.  The collaboration will leverage Graph’s lab-in-the-loop platform with Parse’s GigLab to profile hundreds of millions of cells from patients with immune diseases… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Events #Lab technology #SLAS2026

Expert in AI and drug discovery joins DDW track at SLAS2026

Dr Gabe Musso, Chief Scientific Officer, Lunai Bioworks, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. Dr Gabe Musso, Chief Scientific Officer, Lunai Bioworks He will present: De-Risking the Translation Gap: Coupling AI with… Read More

#News

#Drug discovery #Legal action #Life sciences #Regulatory

Proactive and forward-looking disclosure risks for pharma

Jennifer Windom, Partner at Hogan Lovells, and Bolton Smith, associate at Hogan Lovells, present the risks and considerations pharmaceutical and life sciences companies have to take when making proactive and forward-looking disclosure statements.  Publicly-traded pharmaceutical and life science companies often face a dilemma when addressing future prospects. On the one… Read More

#Exclusive Content